Actively Recruiting
Study Comparing Bioequivalence of Zongertinib Tablets by Two Manufacturers in Healthy Adults Under Fasted and Fed Conditions Using a Randomized Crossover Design
Led by Boehringer Ingelheim · Updated on 2026-09-15
56
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the bioequivalence of Zongertinib tablets produced by two different manufacturers in healthy adult volunteers aged 18 to 50 years. The study aims to understand how the body absorbs the drug when taken as tablets under both fasting and fed conditions. This phase 1, randomized, open-label, crossover trial investigates whether the two formulations behave similarly in the body. Participants receive single oral doses of either the test product Zongertinib Formulation B or the reference product Zongertinib Formulation A in four different sequences involving both fasted and fed states. Each participant experiences all four treatment sequences in a crossover design, allowing direct comparison of the two formulations under varying conditions. During the trial, participants undergo medical evaluations including physical exams, vital signs, ECGs, and laboratory tests to ensure health status. Blood samples are collected up to 72 hours after dosing to measure drug concentration levels and absorption parameters. The primary measures include the area under the concentration-time curve and the maximum concentration of the drug in plasma. This trial involves close monitoring and lasts for the duration needed to complete all treatment sequences and assessments.
CONDITIONS
Brief Title
A Study in Healthy People to Test How Zongertinib is Taken up in the Body When Given as Tablets Made by Two Different Manufacturers With or Without Food
Research Team
B
Boehringer Ingelheim
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here